Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Ipsen Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. January 27, 2023 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI January 20, 2023 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases January 09, 2023 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva December 23, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy December 08, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma November 09, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance October 27, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting October 25, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology August 12, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 August 05, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer August 03, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic August 01, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance July 28, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission June 29, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury June 09, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer May 26, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer May 03, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022 April 27, 2022 From Ipsen Via Business Wire Tickers IPSEY OTC Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer March 25, 2022 From Ipsen Via Business Wire Tickers OTC Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience March 16, 2022 From Ipsen Via Business Wire Tickers OTC Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial February 15, 2022 From Ipsen Via Business Wire Tickers OTC Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business February 11, 2022 From Ipsen Via Business Wire Tickers OTC Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva January 24, 2022 From Ipsen Via Business Wire Tickers OTC Ipsen Nominates Karen Witts as New Independent Board Member January 21, 2022 From Ipsen Via Business Wire Tickers OTC Ipsen Appoints Stewart Campbell Executive Vice President and President of North America November 03, 2021 From Ipsen Via Business Wire Tickers OTC Ipsen Pledges Ambitious Action on Climate Change October 27, 2021 From Ipsen Via Business Wire Tickers OTC Ipsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year Guidance October 21, 2021 From Ipsen Via Business Wire Tickers OTC Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 October 18, 2021 From Ipsen Via Business Wire Tickers OTC Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International October 11, 2021 From Ipsen Via Business Wire Tickers OTC Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer September 18, 2021 From Ipsen Via Business Wire Tickers OTC Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.